Olga Solomon

Head of Unit · EU

Meetings on record

  • 2026-08-28 · Veristat · The meeting has been called at the request of the MAH of the medicinal product Aumseqa in light of intended regulatory action with regard to that medicinal product.
  • 2026-07-16 · CSL · Meeting with CSL Vifor
  • 2026-07-08 · European Federation of Pharmaceutical Industries and Associations · Discussion on AMR incentive metrics on Transferable Exclusivity Voucher (TEV) prepared by EFPIA and related aspects of TEVs
  • 2026-06-04 · European Federation of Pharmaceutical Industries and Associations · Implementation of the new EU pharmaceutical legislation
  • 2026-06-02 · Pharmaceutical Group of the European Union · Availability of medicines, role of pharmacists, pharma package implementation
  • 2026-05-04 · MEDICINES FOR EUROPE · - challenges for generic and biosimilar applicants in accessing reference products
 - clear guidelines on use of reference data for ERA
  • 2025-10-03 · European Federation of Pharmaceutical Industries and Associations · The discussion focused on simplifying Annex II to foster innovation while aligning with ICH guidelines, with ideas for legacy products to gradually transition.
  • 2025-10-03 · Plasma Protein Therapeutics Association Europe, international Association without lucrative purpose · The discussion focused on simplifying Annex II to foster innovation while aligning with ICH guidelines, with ideas for legacy products to gradually transition.
  • 2025-10-03 · Biogen · The discussion focused on simplifying Annex II to foster innovation while aligning with ICH guidelines, with ideas for legacy products to gradually transition.
  • 2025-10-03 · Haleon · The discussion focused on simplifying Annex II to foster innovation while aligning with ICH guidelines, with ideas for legacy products to gradually transition.
  • 2025-10-03 · Merck Sharp & Dohme Europe Belgium SRL · The discussion focused on simplifying Annex II to foster innovation while aligning with ICH guidelines, with ideas for legacy products to gradually transition.
  • 2025-10-03 · STADA Arzneimittel · The discussion focused on simplifying Annex II to foster innovation while aligning with ICH guidelines, with ideas for legacy products to gradually transition.
  • 2025-10-03 · Gemeinsame Schlichtungsstelle der Österreichischen Kreditwirtschaft · The discussion focused on simplifying Annex II to foster innovation while aligning with ICH guidelines, with ideas for legacy products to gradually transition.
  • 2025-10-03 · MEDICINES FOR EUROPE · The discussion focused on simplifying Annex II to foster innovation while aligning with ICH guidelines, with ideas for legacy products to gradually transition.
  • 2025-10-03 · Association of the European Self-Care Industry · The discussion focused on simplifying Annex II to foster innovation while aligning with ICH guidelines, with ideas for legacy products to gradually transition.
  • 2025-10-03 · Vaccines Europe · The discussion focused on simplifying Annex II to foster innovation while aligning with ICH guidelines, with ideas for legacy products to gradually transition.
  • 2025-10-03 · Bayer AG · The discussion focused on simplifying Annex II to foster innovation while aligning with ICH guidelines, with ideas for legacy products to gradually transition.
  • 2025-02-20 · MEDICINES FOR EUROPE · Preparation of participation of Olga Solomon in the Medicines for Europe Regulatory and Scientific Affairs Conference. Exchange of views on the reform of the General Pharmaceutical Legislation.
  • 2025-02-17 · Hellenic Association of Pharmaceutical Companies · Exchange of views on the reform of the General Pharmaceutical Legislation, discussion on the proposed system of incentives

Source: published meeting logs. Listing a meeting does not imply any wrongdoing.